Trial · NCT05618587
Effect of Lithium Therapy on Long COVID Symptoms
NCT05618587, Phase 2, Completed, State University of New York at Buffalo; results first posted 2025-03-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Lithium Therapy on Long COVID Symptoms. Trials, record NCT05618587. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05618587
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Lithium Therapy on Long COVID Symptoms
- NCT number
- NCT05618587
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 52 participants, actual
- Lead sponsor
- State University of New York at Buffalo
- Conditions
- Long COVID
- Interventions
- Lithium, Placebo
- First posted
- 2022-11-16
- Last updated
- 2025-03-05
- Results first posted
- 2025-03-05
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Fatigue Severity Scale | Change from baseline to day 21 | 7-item questionnaire assessing fatigue severity. Score range 1-49 with higher values signifying worse outcome |
| Primary | Brain Fog Severity Scale | Change from baseline to day 21 | 7-item questionnaire assessing brain fog severity. Score range 1-49 with higher values signifying worse outcome |
| Secondary | Patient Global Impression of Change (PGIC) | Day 21 | Change in symptoms on 7-point scale. Single-item scale. Score range 1-7 with higher values signifying better outcome |
| Secondary | Well-Being Scale | Change from baseline to day 21 | Sense of well-being over past week on 10-point scale. Score range 0-10 with higher values signifying better outcome. |
| Secondary | Short Form-12 Health Survey (1-week Modification) | Change from baseline to day 21 | Quality of life assessment over past week, PCS-subscale. 12-item quality of life scale. Score range 0-100 for both the Physical Component Score and the Mental Component Score with higher values signifying better outcomes. |
| Secondary | Desire to Continue Therapy | Day 21 | Single Yes/No question. Single-item scale. Score range 1-2 with higher value signifying better outcome. Reported as % of respondents recording "yes". |
| Secondary | Generalized Anxiety Disorder-2 Scale | Change from baseline to day 21 | 2-item questionnaire assessing anxiety frequency over the past week. 2-item scale. Score range 0-6 with higher values signifying worse outcome |
| Secondary | Headache and Body Pain Bother Scale | Change from baseline to day 21 | 2-item questionnaire assessing frequency of headaches and body pain over the past week, Headache score. 2-item scale. Score range 2-10 with higher values signifying worse outcome |
| Secondary | Insomnia Severity Index | Change from baseline to day 21 | 7-item questionnaire assessing insomnia severity over the past week. 7-item scale. Score range 0-28 with higher values signifying worse outcome. |
| Secondary | Sense of Smell and Taste Change Scale | Day 21 | Subjective change from baseline on a 7-point scale (score range: 1-7) with higher scores indicating better outcomes. Scores of 1 and 7 indicate sense of smell and taste were "very much worse" or "very much improved", respectively, since the start of study treatment. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Fatigue Severity Scale | Change from baseline to day 21 | score on a scale | MEAN | |
| PRIMARY | Brain Fog Severity Scale | Change from baseline to day 21 | score on a scale | MEAN | |
| SECONDARY | Patient Global Impression of Change (PGIC) | Day 21 | score on a scale | MEAN | |
| SECONDARY | Well-Being Scale | Change from baseline to day 21 | score on a scale | MEAN | |
| SECONDARY | Short Form-12 Health Survey (1-week Modification) | Change from baseline to day 21 | score on a scale | MEAN | |
| SECONDARY | Desire to Continue Therapy | Day 21 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Generalized Anxiety Disorder-2 Scale | Change from baseline to day 21 | score on a scale | MEAN | |
| SECONDARY | Headache and Body Pain Bother Scale | Change from baseline to day 21 | score on a scale | MEAN | |
| SECONDARY | Insomnia Severity Index | Change from baseline to day 21 | score on a scale | MEAN | |
| SECONDARY | Sense of Smell and Taste Change Scale | Day 21 | score on a scale | MEAN |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 outcomesResults by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Fatigue Severity Scale | Lithium | -11.3 | Standard Deviation 12.6 | score on a scale | |
| Fatigue Severity Scale | Placebo | -8.6 | Standard Deviation 12.3 | score on a scale | |
| Brain Fog Severity Scale | Lithium | -9.0 | Standard Deviation 13.8 | score on a scale | |
| Brain Fog Severity Scale | Placebo | -8.1 | Standard Deviation 10.6 | score on a scale | |
| Patient Global Impression of Change (PGIC) | Lithium | 4.7 | Standard Deviation 1.1 | score on a scale | |
| Patient Global Impression of Change (PGIC) | Placebo | 4.6 | Standard Deviation 1.2 | score on a scale | |
| Well-Being Scale | Lithium | 1.0 | Standard Deviation 2.0 | score on a scale | |
| Well-Being Scale | Placebo | 0.9 | Standard Deviation 2.1 | score on a scale | |
| Short Form-12 Health Survey (1-week Modification) | Lithium | 5.1 | Standard Deviation 8.5 | score on a scale | |
| Short Form-12 Health Survey (1-week Modification) | Placebo | 4.2 | Standard Deviation 11.1 | score on a scale |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Lithium | 26 | |
| Overall Study | STARTED | Placebo | 26 | |
| Overall Study | COMPLETED | Lithium | 24 | |
| Overall Study | COMPLETED | Placebo | 26 | |
| Overall Study | NOT COMPLETED | Lithium | 2 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Lithium | 0 | 24 |
| Total, all-cause mortality | Placebo | 0 | 26 |
| Total, other adverse events | Lithium | 0 | 24 |
| Total, other adverse events | Placebo | 0 | 26 |
| Total, serious adverse events | Lithium | 0 | 24 |
| Total, serious adverse events | Placebo | 0 | 26 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39356507 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UL1TR001412 | University of Buffalo Clinical and Translational Science Institute | MURPHY, TIMOTHY F | STATE UNIVERSITY OF NEW YORK AT BUFFALO | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2015 to 2024 |
Source NIH RePORTER
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Lithium vs Placebo: deaths from any cause | Trial comparisons |
| Lithium vs Placebo: Desire to Continue Therapy | Trial comparisons |
| Lithium vs Placebo: serious adverse events | Trial comparisons |
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Symbol Coding | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05618587
GET https://conductscience.org/api/trials/v1/NCT05618587/results?page=2